SCHEMBL2360101

SCHEMBL2360101

Cc1ccc(Br)c(C2=NCCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 9/20 0.46
CHRNA3 P32297 9/20 0.46
GAA P10253 3/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 3/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC4 P56524 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
CYP1A2 P05177 1/20 0.34
THRB P10828 1/20 0.34
CYP2C19 P33261 1/20 0.34
NISCH Q9Y2I1 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
CHRNA7 P36544 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22097362 0.82 CHRNB4 (0.49) CHRNB4CHRNA3ALDH1A1HDAC8HDAC4
SCHEMBL22097300 0.79 CHRNB4 (0.46) CHRNB4CHRNA3GAAMAPTKDM4E
SCHEMBL22097422 0.79 NISCH (0.51) CHRNB4CHRNA3GAAMAPTKDM4E
SCHEMBL14194429 0.79 CHRNB4 (0.49) CHRNB4CHRNA3GAAMAPTKDM4E
SCHEMBL2323955 0.74 CHRNB4 (0.47) CHRNB4CHRNA3GAAMAPTKDM4E
SCHEMBL13740749 0.72 CHRNB4 (0.46) CHRNB4CHRNA3GAAMAPTKDM4E
SCHEMBL13407668 0.72 ALDH1A1 (0.43) ALDH1A1CYP1A2THRBKMT2A
SCHEMBL3409001 0.72 PARP1 (0.34) ALDH1A1CYP1A2
SCHEMBL27928338 0.70 CHRNB4 (0.55) CHRNB4CHRNA3MAPTALDH1A1CYP1A2
SCHEMBL25282712 0.69 CHRNB4 (0.55) CHRNB4CHRNA3MAPTALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356105-B1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN MSD OSS BV (NL) 2013-04-10 EP disclosed
US-8188123-B2 (Pyrrolidin-2-yl)phenyl derivatives MERCK SHARP & DOHME B.V. (NL) 2012-05-29 US disclosed
EP-2356105-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. Organon (NL) 2011-08-17 EP disclosed
WO-2010052198-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. ORGANON (NL) 2010-05-14 WO disclosed
US-20100113493-A1 (PYRROLIDIN-2-YL)PHENYL DERIVATIVES N.V. ORGANON 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113493-A1 (PYRROLIDIN-2-YL)PHENYL DERIVATIVES CNR1, CNR2, TRPV1 CHRNB4 1647/4885CHRNA3 1480/4885GAA 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.